Drug Class Review on Angiotensin II Receptor Antagonists

Final Report

Published in: Drug Effectiveness Review Project , (Mark Helfand, MD: Oregon Evidence-based Practice Center, Oregon Health & Science University), Feb. 2006, p. 1-87

Posted on RAND.org on December 31, 2005

by Elaine Furmaga, Peter Glassman, Shannon Rhodes, Marika Booth, Walter Mojica, Sally C. Morton, Paul G. Shekelle

Read More

Access further information on this document at www.ohsu.edu

This article was published outside of RAND. The full text of the article can be found at the link above.

Drug Effectiveness Review Project (DERP) is a collaboration of public entities (the Center for Evidence-based Policy and the Oregon Evidence-based Practice Center) who have joined together to produce systematic, evidence-based reviews of the comparative effectiveness and safety of drugs in many widely used drug classes, and to apply the findings to inform public policy and related activities in local settings.

Research conducted by

This report is part of the RAND Corporation external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.